Samsung Bioepis Boasts Positive Data On Lucentis And Herceptin Biosimilars
Post-Hoc Analysis And Five-Year Follow-Up Data Published By Firm
Ahead of launching potentially its Lucentis biosimilar in the EU early next year, Samsung Bioepis has reported two lots of positive analysis involving its Byooviz biosimilar, at the same time as it disclosed the findings of a five-year follow-up study for its trastuzumab biosimilar, Ontruzant.
